First patients sought for groundbreaking cancer drug trial
NCT ID NCT07481357
Summary
This is the first study in people to test a new drug called DA 3501 for advanced stomach and pancreatic cancers. The main goals are to find a safe and effective dose and to see how the body handles the drug. About 51 patients with specific types of these cancers will receive the drug once every three weeks while doctors monitor their health and tumor response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.